Search Results 2551-2560 of 18205 for rheumatoid arthritis

  1. Spinal cord tumor - Doctors and departments - Mayo Clinic

    ... Arthritis, Strain, Foot drop, Muscle atrophy, Neurologic muscle weakness, Neuropathy, Muscle weakness, Gait unsteadiness, Parkinsonism, Cancer-related pain ...

  2. Autologous Alpha-2 Macroglobulin Rich Plasma, Safety and Efficacy in Symptomatic Moderate Knee Osteoarthritis - Mayo Clinic

    ... arthritis, arthropathy of the knee associated with juxta-articular Paget's disease of the femur or tibia, ochronosis, hemophilic arthropathy, systemic ...

  3. Publications - Sanjeev Nanda, M.D. - Mayo Clinic

    Arthritis Res Ther. 2018 Feb 27; 20 (1):37. View PubMed; Koball AM, Mueller PS, Craner J, Clark MM, Nanda S, Kebede EB, Grothe KB. Crucial conversations about ...

  4. Radiation therapy - Mayo Clinic

    Radiation therapy, also called radiotherapy, is a type of cancer treatment. This treatment uses beams of intense energy to kill cancer cells.

  5. Orthopedic Biomechanics Research - Overview

    ... Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the Department of Defense, Regenerative Medicine Minnesota and other organizations. Projects ...

  6. Joel Streed | Mayo Clinic News Network - Page 62 of 170

    Osteoarthritis is the most common form of arthritis, affecting millions of people worldwide. It occurs when the protective cartilage on the ends of your ...

  7. COVID-19 update / healthy mindset for back to school / reversing heart disease / regenerative medicine - Mayo Clinic News Network

    Arthritis / reversing heart disease / regenerative medicine. Arthritis / reversing heart disease / regenerative medicineDec. 12, 2020. By Jennifer O'Hara ...

  8. Skin Cancer Clinical Trials - Mayo Clinic Research

    Understanding how to better predict and manage patients at high risk for rheumatic irAEs and tailor therapy without diminishing cancer treatment efficacy and, ...

  9. Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients with Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorder - Mayo Clinic

    Hematopoietic growth factors: ≥ 14 days after the last dose of a long-acting growth factor (e.g., Neulasta) or 7 days for short-acting growth factor; for ...

  10. Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma - Mayo Clinic

    ... factor [G-CSF], granulocyte macrophage colony-stimulating factor [GM-CSF], or recombinant erythropoietin) within 4 weeks prior to study treatment. Patient ...